Tango Therapeutics TNGX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $159.97M+42.5% | $112.28M+84.4% | $60.91M+45.6% | $41.84M-31.4% | $61M-12.3% | ||
| $222.01M-3.8% | $230.86M+144% | $94.47M-33.2% | $141.51M-10.6% | $158.29M-16.0% | ||
| $392.33M+10.9% | $353.76M+116% | $163.78M-13.8% | $190.1M-15.5% | $224.93M-15.5% | ||
| $6.38M-7.1% | $6.87M-6.5% | $7.35M-5.7% | $7.79M+3.3% | $7.54M-6.9% | ||
| $435.79M+9.3% | $398.69M+89.7% | $210.14M-11.7% | $237.89M-13.3% | $274.31M-13.3% | ||
| $14.33M-33.9% | $21.68M+17.5% | $18.44M-53.9% | $40.03M+11.4% | $35.92M-5.9% | ||
| $44.29M-15.7% | $52.51M+4.8% | $50.11M-51.3% | $102.94M-4.3% | $107.55M-8.1% | ||
| 400M+100% | 200M-50.0% | 400M0.0% | 400M+100% | 200M+185,085% | ||
| -$648.67M-7.5% | -$603.15M-6.9% | -$564.4M+2.7% | -$580.29M-7.2% | -$541.43M-8.0% | ||
| $391.51M+13.1% | $346.18M+116% | $160.03M+18.6% | $134.95M-19.1% | $166.76M-16.4% | ||
| $435.79M+9.3% | $398.69M+89.7% | $210.14M-11.7% | $237.89M-13.3% | $274.31M-13.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Tango Therapeutics cover its short-term obligations?
- Its current ratio is 27.38 — current assets exceed current liabilities.
- Where does Tango Therapeutics's balance sheet data come from?
- Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.